Mumbai, India and Naples, Italy, August 17, 2026
Lupin Limited, a global pharmaceutical company, announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg. The FDA approval allows Lupin to market its generic pitolisant tablets in the United States after determining that the product is bioequivalent to Wakix® for the indications included in the approved labeling. The regulatory milestone expands Lupin’s U.S. portfolio of complex pharmaceutical products and strengthens its presence in the central nervous system (CNS) therapeutic area. The approval also highlights the company’s continued focus on developing and commercializing generic medicines that meet U.S. regulatory and quality requirements.
U.S. FDA Approves Lupin’s Pitolisant Tablets
The U.S. FDA final approval covers Lupin’s Pitolisant Tablets in two strengths, 4.45 mg and 17.8 mg. The product has been approved as bioequivalent to Wakix®, the reference product, for the indications described in the FDA-approved labeling. Bioequivalence is a key regulatory requirement for generic medicines because it demonstrates that the generic product performs in the body in a manner comparable to the reference drug. Lupin’s approval therefore represents an important regulatory achievement for the company as it expands its U.S. generic pharmaceutical portfolio. The availability of an approved generic version can also contribute to broader access to established pharmaceutical therapies, subject to market conditions and prescribing requirements. The approval further demonstrates Lupin’s capabilities in navigating the U.S. ANDA regulatory pathway for pharmaceutical products across specialized therapeutic categories.
Pitolisant Expands Lupin’s CNS Portfolio
Pitolisant is associated with the central nervous system (CNS) therapeutic area, one of the major areas in which Lupin has established pharmaceutical expertise. Lupin develops and supplies branded and generic medicines across several therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, CNS, and women’s health. The FDA approval of Pitolisant Tablets adds another product to the company’s growing U.S. portfolio and supports its strategy of providing pharmaceutical products across a broad range of patient needs. The approved strengths of 4.45 mg and 17.8 mg provide dosing options consistent with the FDA-approved labeling for the generic product. For cGxP.wire readers, the announcement is particularly relevant because it represents a completed regulatory milestone involving bioequivalence, generic drug development, and U.S. pharmaceutical approval.
Advertisement
Lupin Strengthens Global Pharmaceutical Operations
Headquartered in Mumbai, India, Lupin operates as a global pharmaceutical company with products distributed across more than 100 markets. Its portfolio includes branded formulations, generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs). The company operates 15 manufacturing sites and six research centers globally, supported by a workforce of more than 26,000 professionals. Lupin has maintained a significant presence in both the Indian and U.S. pharmaceutical markets, with its operations supported by research, manufacturing, regulatory, and commercial capabilities. The company also operates through subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, reflecting its broader healthcare and life-sciences activities. The approval of Pitolisant Tablets reinforces Lupin’s ongoing focus on expanding its pharmaceutical portfolio through regulatory submissions and product development. As the U.S. remains one of the world’s largest pharmaceutical markets, successful FDA approvals continue to represent important milestones for global generic drug manufacturers. Lupin’s latest approval demonstrates its continued progress in bringing FDA-approved generic medicines to the U.S. market while strengthening its position across important therapeutic areas.
Source: Lupin Limited press relese
